What makes a patient a good candidate for treatments targeting amyloid such as lecanemab or donanemab?

Are there patients in whom you would specifically avoid this class of treatments?

Answer from: at Academic Institution

All the amyloid antibody trials were conducted in patients without the burden of cerebrovascular disease we often see in clinic populations. Many individuals with cognitive impairment have both vascular and neurogenerative contributions to their decline. We don’t yet know from real-world exper...

Answer from: at Community Practice

Lecanemab and donanemab were studied in patients with mild cognitive impairment or mild dementia due to Alzheimer's disease. Confirmation with biomarkers and exclusion of other possible causes of dementia is required.

Comments

at Riverside Medical Group
Do you usually check amyloid PET or CSF amyloid? A...

Please select the option that best describes you:

What makes a patient a good candidate for treatments targeting amyloid such as lecanemab or donanemab?

Related Questions